The shares of Pfizer Inc. tumbled more than 4% on Monday following the news the pharma giant decided to halt the development of its experimental obesity pill lotiglipron.
Ahead of the session, Pfizer said it stopped the trials due to elevated liver enzymes in patients who took the treatment once a day. While patients didn't experience side effects, this could indicate damage to cells in the liver.
Pfizer's stocks sank 4.22% to $36.68 apiece at 9:56 am ET to their lowest in over a month.
